Catalent has been contracted to make supplies of an extended-release drug for Parkinson’s disease (PD) patients set to enter Phase III trials by developer Adamas Pharmaceuticals.
The deal – financial terms of which have not been disclosed – will see Catalant make ADS-5102 (amantadine HCl) for assessment as a treatment for Levodopa-Induced Dyskinesia (LID) in patients with Parkinson’s disease.
Adamas CEO Gregory Went said: “We believe Catalent’s capabilities make them the right choice to support execution of our upcoming clinical trials.”
This was echoed by Barry Littlejohns, President of Catalent’s Advanced Delivery Technologies business, who said: “Our controlled release formulation expertise and drug delivery technologies will ultimately benefit patients with better treatments.
“We are pleased Adamas selected Catalent for the development and supply of ADS-5102 which, if approved, will be the first medical treatment indicated for patients with LID in Parkinson’s disease.”